Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice

Journal of Immunology

Volumn 194, Issue 4, 2015, Pages 1695-1701

  Manning, Michael L ^a   Mason Osann, Emily ^a,b   Onda, Masanori ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; NEUTRALIZING ANTIBODY; PENTOSTATIN; RECOMBINANT IMMUNOTOXIN ANTIBODY; TOXIN ANTIBODY; UNCLASSIFIED DRUG; BACTERIAL TOXIN; BORONIC ACID DERIVATIVE; EXOTOXIN; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; RECOMBINANT PROTEIN; SS1(DSFV)PE38; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BONE MARROW; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; IMMUNOMODULATION; MOUSE; NONHUMAN; PLASMA CELL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BACTERIAL TOXINS; BORONIC ACIDS; BORTEZOMIB; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXOTOXINS; FEMALE; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; PROTEASOME INHIBITORS; PYRAZINES; RECOMBINANT PROTEINS; VIRULENCE FACTORS;

EID: 84922569110     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402324     Document Type: Article

References (32)

1. Wang, J., J. Lozier, G. Johnson, S. Kirshner, D. Verthelyi, A. Pariser, E. Shores, and A. Rosenberg. 2008. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat. Biotechnol. 26: 901-908.
2. Baker, M. P., H. M. Reynolds, B. Lumicisi, and C. J. Bryson. 2010. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself 1: 314-322.
3. Naumann, M., L. M. Boo, A. H. Ackerman, and C. J. Gallagher. 2013. Immunogenicity of botulinum toxins. J. Neural Transm. 120: 275-290.
4. Schellekens, H. 2005. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 20(Suppl. 6): vi3-vi9.
5. Wayne, A. S., D. J. Fitzgerald, R. J. Kreitman, and I. Pastan. 2014. Immunotoxins for leukemia. Blood 123: 2470-2477.
6. Hassan, R., A. C. Miller, E. Sharon, A. Thomas, J. C. Reynolds, A. Ling, R. J. Kreitman, M. M. Miettinen, S. M. Steinberg, D. H. Fowler, and I. Pastan. 2013. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci. Transl. Med. 5: ra147.
7. Mossoba, M. E., M. Onda, J. Taylor, P. R. Massey, S. Treadwell, E. Sharon, R. Hassan, I. Pastan, and D. H. Fowler. 2011. Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin. Cancer Res. 17: 3697-3705.
8. Gomez, A. M., N. Willcox, P. C. Molenaar, W. Buurman, P. Martinez-Martinez, M. H. De Baets, and M. Losen. 2012. Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis? Ann. N. Y. Acad. Sci. 1274: 48-59.
9. Obeng, E. A., L. M. Carlson, D. M. Gutman, W. J. Harrington, Jr., K. P. Lee, and L. H. Boise. 2006. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107: 4907-4916.
10. Meister, S., U. Schubert, K. Neubert, K. Herrmann, R. Burger, M. Gramatzki, S. Hahn, S. Schreiber, S. Wilhelm, M. Herrmann, et al. 2007. Extensive im-munoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 67: 1783-1792.
11. Antignani, A., and D. Fitzgerald. 2013. Immunotoxins: the role of the toxin. Toxins (Basel) 5: 1486-1502.
12. Hassan, R., S. Bullock, A. Premkumar, R. J. Kreitman, H. Kindler, M. C. Willingham, and I. Pastan. 2007. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res. 13: 5144-5149.
13. Kreitman, R. J., M. S. Tallman, T. Robak, S. Coutre, W. H. Wilson, M. StetlerStevenson, D. J. Fitzgerald, R. Lechleider, and I. Pastan. 2012. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol. 30: 1822-1828.
14. Liu, W., M. Onda, C. Kim, L. Xiang, J. E. Weldon, B. Lee, and I. Pastan. 2012. A recombinant immunotoxin engineered for increased stability by adding a disul-fide bond has decreased immunogenicity. Protein Eng. Des. Sel. 25: 1-6.
15. Onda, M., R. Beers, L. Xiang, S. Nagata, Q.-C. Wang, and I. Pastan. 2008. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc. Natl. Acad. Sci. USA 105: 11311-11316.
16. Onda, M., R. Beers, L. Xiang, B. Lee, J. E. Weldon, R. J. Kreitman, and I. Pastan. 2011. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc. Natl. Acad. Sci. USA 108: 5742-5747.
17. Weldon, J. E., L. Xiang, J. Zhang, R. Beers, D. A. Walker, M. Onda, R. Hassan, and I. Pastan. 2013. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol. Cancer Ther. 12: 48-57.
18. Onda, M., S. Nagata, D. J. FitzGerald, R. Beers, R. J. Fisher, J. J. Vincent, B. Lee, M. Nakamura, J. Hwang, R. J. Kreitman, et al. 2006. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J. Immunol. 177: 8822-8834.
19. Onda, M., M. Willingham, S. Nagata, T. K. Bera, R. Beers, M. Ho, R. Hassan, R. J. Kreitman, and I. Pastan. 2005. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin. Cancer Res. 11: 5840-5846.
20. Neubert, K., S. Meister, K. Moser, F. Weisel, D. Maseda, K. Amann, C. Wiethe, T. H. Winkler, J. R. Kalden, R. A. Manz, and R. E. Voll. 2008. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14: 748-755.
21. Mulder, A., S. Heidt, M. Vergunst, D. L. Roelen, and F. H. J. Claas. 2013. Proteasome inhibition profoundly affects activated human B cells. Transplantation 95: 1331-1337.
22. Moreau, P., H. Pylypenko, S. Grosicki, I. Karamanesht, X. Leleu, M. Grishunina, G. Rekhtman, Z. Masliak, T. Robak, A. Shubina, et al. 2011. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 12: 431-440.
23. Vieira, P., and K. Rajewsky. 1988. The half-lives of serum immunoglobulins in adult mice. Eur. J. Immunol. 18: 313-316.
24. Weiss, M. A., P. G. Maslak, J. G. Jurcic, D. A. Scheinberg, T. B. Aliff, N. Lamanna, S. R. Frankel, S. E. Kossman, and D. Horgan. 2003. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 21: 1278-1284.
25. Oracki, S. A., J. A. Walker, M. L. Hibbs, L. M. Corcoran, and D. M. Tarlinton. 2010. Plasma cell development and survival. Immunol. Rev. 237: 140-159.
26. Lu, L. D., K. L. Stump, N. H. Wallace, P. Dobrzanski, C. Serdikoff, D. E. Gingrich, B. J. Dugan, T. S. Angeles, M. S. Albom, J. L. Mason, et al. 2011. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. J. Immunol. 187: 3840-3853.
27. Haaijman, J. J., H. R. Schuit, and W. Hijmans. 1977. Immunoglobulin-containing cells in different lymphoid organs of the CBA mouse during its life-span. Immunology 32: 427-434.
28. Radbruch, A., G. Muehlinghaus, E. O. Luger, A. Inamine, K. G. C. Smith, T. D örner, and F. Hiepe. 2006. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6: 741-750.
29. Banugaria, S. G., S. N. Prater, J. K. McGann, J. D. Feldman, J. A. Tannenbaum, C. Bailey, R. Gera, R. L. Conway, D. Viskochil, J. A. Kobori, et al. 2013. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet. Med. 15: 123-131.
30. Argyriou, A. A., G. Iconomou, and H. P. Kalofonos. 2008. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112: 1593-1599.
31. Bringhen, S., M. T. Petrucci, A. Larocca, C. Conticello, D. Rossi, V. Magarotto, P. Musto, L. Boccadifuoco, M. Offidani, P. Omedé, et al. 2014. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 124: 63-69.
32. Onda, M., K. Ghoreschi, S. Steward-Tharp, C. Thomas, J. J. O'Shea, I. H. Pastan, and D. J. Fitz Gerald. 2014. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J. Immunol. 193: 48-55.